---
document_datetime: 2025-12-29 11:57:13
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/deltyba.html
document_name: deltyba.html
version: success
processing_time: 0.1231679
conversion_datetime: 2025-12-31 03:50:12.567865
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Deltyba

[RSS](/en/individual-human-medicine.xml/66325)

##### Authorised

This medicine is authorised for use in the European Union

delamanid Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Deltyba](#news-on)
- [More information on Deltyba](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Deltyba is a medicine that is used in adults, adolescents, children and infants weighing at least 10 kg who have tuberculosis affecting the lung and that is multi-drug resistant (resistant to at least isoniazid and rifampicin, the two standard tuberculosis medicines).

It is used together with other tuberculosis medicines and only when other standard medicine cannot be used either because the disease is resistant to them or because of their side effects.

Deltyba contains the active substance delamanid.

Tuberculosis is rare in the EU, and Deltyba was designated an 'orphan medicine' (a medicine used in rare diseases) on 1 February 2008. Further information on the orphan designation can be found here: [ema.europa.eu/en/medicines/human/orphan-designations/eu307524](/en/medicines/human/orphan-designations/eu-3-07-524)

Expand section

Collapse section

## How is Deltyba used?

Deltyba can only be obtained with a prescription and treatment should be started and monitored by a doctor who is experienced in the treatment of multi-drug resistant tuberculosis. It should be used according to official guidelines on treating multi-drug resistant tuberculosis.

The medicine is available as 50 mg tablets and 25 mg dispersible tables which are taken with food. The 25 mg dispersible tablets are only for children and infants weighing between 10 and 30 kg. The recommended dose for adults is 100 mg twice a day, while the dose for children and infants depends on the patient's body weight.

Deltyba is given for 6 months together with other tuberculosis medicines. Treatment with these medicines should continue after Deltyba treatment, as recommended by official guidelines. For more information about using Deltyba, see the package leaflet or contact a doctor or pharmacist.

## How does Deltyba work?

Tuberculosis is an infection caused by the bacterium *Mycobacterium tuberculosis* ( *M. tuberculosis* ). The active substance in Deltyba, delamanid, is an antibiotic active against *M. tuberculosis* . Although the way it works is unclear, delamanid is known to block the production of methoxy-mycolic and keto-mycolic acids, two essential components of the cell walls of *M. tuberculosis,* which will cause the bacteria to die.

## What benefits of Deltyba have been shown in studies?

The effects of Deltyba have been looked at in one main study involving 481 adults with tuberculosis resistant to standard treatments. Patients in the study were given Deltyba or placebo (a dummy treatment) for 2 months in addition to their other treatments. The main measure of effectiveness was the proportion of patients who no longer had the bacteria in their sputum (phlegm). After 2 months of treatment more than 40% of the patients who were taking Deltyba no longer had the bacteria in their sputum compared with 30% of the patients who were taking placebo.

After the main study had finished, patients had the option to receive treatment with Deltyba for 6 months in an extension study. In addition, a majority of patients who entered the main study were followed up for up to 24 months afterwards. Looking at the results of these follow-up studies together, 2 years after starting treatment 75% of patients who received Deltyba for 6 months or more had no bacteria in their sputum compared with 55% of patients who received Deltyba for 2 months or less.

Additional data indicate that the medicine will be as effective in children, including infants, as it is in adults.

## What are the risks associated with Deltyba?

The most common side effects with Deltyba (which may affect more than 1 patient in 10) are nausea, vomiting, headache, insomnia (sleeping problems), dizziness, tinnitus (ringing or buzzing in the ears), blood tests showing low potassium levels in the blood, gastritis (inflammation of the stomach lining), decreased appetite and weakness. For the full list of side effects of Deltyba, see the package leaflet.

Deltyba must not be used in patients who have low levels of albumin (a blood protein). It must also not be used in patients who are taking certain other medicines that affect the way Deltyba is broken down in the body. For the full list of restrictions, see the package leaflet.

## Why is Deltyba authorised in the EU?

The European Medicines Agency decided that Deltyba's benefits are greater than its risks and it can be authorised for use in the EU. The Agency considered that the benefits of Deltyba had been shown for patients with multi-drug resistant tuberculosis affecting the lung. Although the main study was of short duration and the follow-up studies had shortcomings, the Agency considered that the effects shown after the initial 2 months of treatment are likely to be sustained for the full treatment duration. The Agency noted that an on-going clinical study will provide confirmation on the long-term effectiveness.

The safety profile was considered manageable and several measures were introduced to minimise the risks, including a study to confirm the long-term safety. Furthermore, the medical need for new agents to treat multi-drug resistant tuberculosis was highlighted.

Deltyba has been given 'conditional authorisation'. This means that there is more evidence to come about the medicine, which the company is required to provide. Every year, the European Medicines Agency will review any new information that becomes available and this overview will be updated as necessary.

## What information is still awaited for Deltyba?

Since Deltyba has been given conditional authorisation, the company that markets Deltyba will carry out further studies to confirm the long-term effectiveness and safety of Deltyba.

## What measures are being taken to ensure the safe and effective use of Deltyba?

The company that markets Deltyba will provide educational material for healthcare professionals, explaining how to use the medicine safely to avoid problems such as the development of resistance and side effects on the heart, as well as the risks in pregnancy or women who are breast-feeding.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Deltyba have also been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Deltyba are continuously monitored. Side effects reported with Deltyba are carefully evaluated and any necessary action taken to protect patients.

## Other information about Deltyba

Deltyba received a marketing authorisation valid throughout the European Union on 28 April 2014.

Deltyba : EPAR - Medicine overview

Reference Number: EMA/584075/2020

English (EN) (125.88 KB - PDF)

**First published:** 08/05/2014

**Last updated:** 28/10/2021

[View](/en/documents/overview/deltyba-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-368)

български (BG) (150.16 KB - PDF)

**First published:**

08/05/2014

**Last updated:**

28/10/2021

[View](/bg/documents/overview/deltyba-epar-medicine-overview_bg.pdf)

español (ES) (117.55 KB - PDF)

**First published:**

08/05/2014

**Last updated:**

28/10/2021

[View](/es/documents/overview/deltyba-epar-medicine-overview_es.pdf)

čeština (CS) (141.37 KB - PDF)

**First published:**

08/05/2014

**Last updated:**

28/10/2021

[View](/cs/documents/overview/deltyba-epar-medicine-overview_cs.pdf)

dansk (DA) (115.59 KB - PDF)

**First published:**

08/05/2014

**Last updated:**

28/10/2021

[View](/da/documents/overview/deltyba-epar-medicine-overview_da.pdf)

Deutsch (DE) (119.63 KB - PDF)

**First published:**

08/05/2014

**Last updated:**

28/10/2021

[View](/de/documents/overview/deltyba-epar-medicine-overview_de.pdf)

eesti keel (ET) (113.5 KB - PDF)

**First published:**

08/05/2014

**Last updated:**

28/10/2021

[View](/et/documents/overview/deltyba-epar-medicine-overview_et.pdf)

ελληνικά (EL) (152.29 KB - PDF)

**First published:**

08/05/2014

**Last updated:**

28/10/2021

[View](/el/documents/overview/deltyba-epar-medicine-overview_el.pdf)

français (FR) (118.72 KB - PDF)

**First published:**

08/05/2014

**Last updated:**

28/10/2021

[View](/fr/documents/overview/deltyba-epar-medicine-overview_fr.pdf)

hrvatski (HR) (139.01 KB - PDF)

**First published:**

08/05/2014

**Last updated:**

28/10/2021

[View](/hr/documents/overview/deltyba-epar-medicine-overview_hr.pdf)

italiano (IT) (116.59 KB - PDF)

**First published:**

08/05/2014

**Last updated:**

28/10/2021

[View](/it/documents/overview/deltyba-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (154.85 KB - PDF)

**First published:**

08/05/2014

**Last updated:**

28/10/2021

[View](/lv/documents/overview/deltyba-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (139.28 KB - PDF)

**First published:**

08/05/2014

**Last updated:**

28/10/2021

[View](/lt/documents/overview/deltyba-epar-medicine-overview_lt.pdf)

magyar (HU) (139.97 KB - PDF)

**First published:**

08/05/2014

**Last updated:**

28/10/2021

[View](/hu/documents/overview/deltyba-epar-medicine-overview_hu.pdf)

Malti (MT) (141.42 KB - PDF)

**First published:**

08/05/2014

**Last updated:**

28/10/2021

[View](/mt/documents/overview/deltyba-epar-medicine-overview_mt.pdf)

Nederlands (NL) (116.11 KB - PDF)

**First published:**

08/05/2014

**Last updated:**

28/10/2021

[View](/nl/documents/overview/deltyba-epar-medicine-overview_nl.pdf)

polski (PL) (143.1 KB - PDF)

**First published:**

08/05/2014

**Last updated:**

28/10/2021

[View](/pl/documents/overview/deltyba-epar-medicine-overview_pl.pdf)

português (PT) (118.02 KB - PDF)

**First published:**

08/05/2014

**Last updated:**

28/10/2021

[View](/pt/documents/overview/deltyba-epar-medicine-overview_pt.pdf)

română (RO) (146.54 KB - PDF)

**First published:**

08/05/2014

**Last updated:**

28/10/2021

[View](/ro/documents/overview/deltyba-epar-medicine-overview_ro.pdf)

slovenčina (SK) (140.38 KB - PDF)

**First published:**

08/05/2014

**Last updated:**

28/10/2021

[View](/sk/documents/overview/deltyba-epar-medicine-overview_sk.pdf)

slovenščina (SL) (138.66 KB - PDF)

**First published:**

08/05/2014

**Last updated:**

28/10/2021

[View](/sl/documents/overview/deltyba-epar-medicine-overview_sl.pdf)

Suomi (FI) (114.05 KB - PDF)

**First published:**

08/05/2014

**Last updated:**

28/10/2021

[View](/fi/documents/overview/deltyba-epar-medicine-overview_fi.pdf)

svenska (SV) (115.93 KB - PDF)

**First published:**

08/05/2014

**Last updated:**

28/10/2021

[View](/sv/documents/overview/deltyba-epar-medicine-overview_sv.pdf)

Deltyba : EPAR - Risk management plan

English (EN) (4.05 MB - PDF)

**First published:** 28/10/2021

**Last updated:** 05/05/2025

[View](/en/documents/rmp/deltyba-epar-risk-management-plan_en.pdf)

## Product information

Deltyba : EPAR - Product Information

English (EN) (398.32 KB - PDF)

**First published:** 08/05/2014

**Last updated:** 05/05/2025

[View](/en/documents/product-information/deltyba-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-501)

български (BG) (557.27 KB - PDF)

**First published:**

08/05/2014

**Last updated:**

05/05/2025

[View](/bg/documents/product-information/deltyba-epar-product-information_bg.pdf)

español (ES) (445.61 KB - PDF)

**First published:**

08/05/2014

**Last updated:**

05/05/2025

[View](/es/documents/product-information/deltyba-epar-product-information_es.pdf)

čeština (CS) (565.62 KB - PDF)

**First published:**

08/05/2014

**Last updated:**

05/05/2025

[View](/cs/documents/product-information/deltyba-epar-product-information_cs.pdf)

dansk (DA) (439.29 KB - PDF)

**First published:**

08/05/2014

**Last updated:**

05/05/2025

[View](/da/documents/product-information/deltyba-epar-product-information_da.pdf)

Deutsch (DE) (513.84 KB - PDF)

**First published:**

08/05/2014

**Last updated:**

05/05/2025

[View](/de/documents/product-information/deltyba-epar-product-information_de.pdf)

eesti keel (ET) (486.77 KB - PDF)

**First published:**

08/05/2014

**Last updated:**

05/05/2025

[View](/et/documents/product-information/deltyba-epar-product-information_et.pdf)

ελληνικά (EL) (542.83 KB - PDF)

**First published:**

08/05/2014

**Last updated:**

05/05/2025

[View](/el/documents/product-information/deltyba-epar-product-information_el.pdf)

français (FR) (536.99 KB - PDF)

**First published:**

08/05/2014

**Last updated:**

05/05/2025

[View](/fr/documents/product-information/deltyba-epar-product-information_fr.pdf)

hrvatski (HR) (515.58 KB - PDF)

**First published:**

08/05/2014

**Last updated:**

05/05/2025

[View](/hr/documents/product-information/deltyba-epar-product-information_hr.pdf)

íslenska (IS) (487.63 KB - PDF)

**First published:**

08/05/2014

**Last updated:**

05/05/2025

[View](/is/documents/product-information/deltyba-epar-product-information_is.pdf)

italiano (IT) (509.52 KB - PDF)

**First published:**

08/05/2014

**Last updated:**

05/05/2025

[View](/it/documents/product-information/deltyba-epar-product-information_it.pdf)

latviešu valoda (LV) (533.61 KB - PDF)

**First published:**

08/05/2014

**Last updated:**

05/05/2025

[View](/lv/documents/product-information/deltyba-epar-product-information_lv.pdf)

lietuvių kalba (LT) (536.97 KB - PDF)

**First published:**

08/05/2014

**Last updated:**

05/05/2025

[View](/lt/documents/product-information/deltyba-epar-product-information_lt.pdf)

magyar (HU) (534.55 KB - PDF)

**First published:**

08/05/2014

**Last updated:**

05/05/2025

[View](/hu/documents/product-information/deltyba-epar-product-information_hu.pdf)

Malti (MT) (612.88 KB - PDF)

**First published:**

08/05/2014

**Last updated:**

05/05/2025

[View](/mt/documents/product-information/deltyba-epar-product-information_mt.pdf)

Nederlands (NL) (460.66 KB - PDF)

**First published:**

08/05/2014

**Last updated:**

05/05/2025

[View](/nl/documents/product-information/deltyba-epar-product-information_nl.pdf)

norsk (NO) (482.66 KB - PDF)

**First published:**

08/05/2014

**Last updated:**

05/05/2025

[View](/no/documents/product-information/deltyba-epar-product-information_no.pdf)

polski (PL) (528.42 KB - PDF)

**First published:**

08/05/2014

**Last updated:**

05/05/2025

[View](/pl/documents/product-information/deltyba-epar-product-information_pl.pdf)

português (PT) (500.24 KB - PDF)

**First published:**

08/05/2014

**Last updated:**

05/05/2025

[View](/pt/documents/product-information/deltyba-epar-product-information_pt.pdf)

română (RO) (542.11 KB - PDF)

**First published:**

08/05/2014

**Last updated:**

05/05/2025

[View](/ro/documents/product-information/deltyba-epar-product-information_ro.pdf)

slovenčina (SK) (565.21 KB - PDF)

**First published:**

08/05/2014

**Last updated:**

05/05/2025

[View](/sk/documents/product-information/deltyba-epar-product-information_sk.pdf)

slovenščina (SL) (510.61 KB - PDF)

**First published:**

08/05/2014

**Last updated:**

05/05/2025

[View](/sl/documents/product-information/deltyba-epar-product-information_sl.pdf)

Suomi (FI) (484.61 KB - PDF)

**First published:**

08/05/2014

**Last updated:**

05/05/2025

[View](/fi/documents/product-information/deltyba-epar-product-information_fi.pdf)

svenska (SV) (436.97 KB - PDF)

**First published:**

08/05/2014

**Last updated:**

05/05/2025

[View](/sv/documents/product-information/deltyba-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** R/0076 25/04/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Deltyba : EPAR - All Authorised presentations

English (EN) (16.69 KB - PDF)

**First published:** 08/05/2014

**Last updated:** 28/10/2021

[View](/en/documents/all-authorised-presentations/deltyba-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-142)

български (BG) (40.39 KB - PDF)

**First published:**

08/05/2014

**Last updated:**

28/10/2021

[View](/bg/documents/all-authorised-presentations/deltyba-epar-all-authorised-presentations_bg.pdf)

español (ES) (14.53 KB - PDF)

**First published:**

08/05/2014

**Last updated:**

28/10/2021

[View](/es/documents/all-authorised-presentations/deltyba-epar-all-authorised-presentations_es.pdf)

čeština (CS) (24.89 KB - PDF)

**First published:**

08/05/2014

**Last updated:**

28/10/2021

[View](/cs/documents/all-authorised-presentations/deltyba-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (14.88 KB - PDF)

**First published:**

08/05/2014

**Last updated:**

28/10/2021

[View](/da/documents/all-authorised-presentations/deltyba-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (14.96 KB - PDF)

**First published:**

08/05/2014

**Last updated:**

28/10/2021

[View](/de/documents/all-authorised-presentations/deltyba-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (18.05 KB - PDF)

**First published:**

08/05/2014

**Last updated:**

28/10/2021

[View](/et/documents/all-authorised-presentations/deltyba-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (40.31 KB - PDF)

**First published:**

08/05/2014

**Last updated:**

28/10/2021

[View](/el/documents/all-authorised-presentations/deltyba-epar-all-authorised-presentations_el.pdf)

français (FR) (17.69 KB - PDF)

**First published:**

08/05/2014

**Last updated:**

28/10/2021

[View](/fr/documents/all-authorised-presentations/deltyba-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (38.19 KB - PDF)

**First published:**

08/05/2014

**Last updated:**

28/10/2021

[View](/hr/documents/all-authorised-presentations/deltyba-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (14.34 KB - PDF)

**First published:**

08/05/2014

**Last updated:**

28/10/2021

[View](/is/documents/all-authorised-presentations/deltyba-epar-all-authorised-presentations_is.pdf)

italiano (IT) (13.54 KB - PDF)

**First published:**

08/05/2014

**Last updated:**

28/10/2021

[View](/it/documents/all-authorised-presentations/deltyba-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (37.3 KB - PDF)

**First published:**

08/05/2014

**Last updated:**

28/10/2021

[View](/lv/documents/all-authorised-presentations/deltyba-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (40.37 KB - PDF)

**First published:**

08/05/2014

**Last updated:**

28/10/2021

[View](/lt/documents/all-authorised-presentations/deltyba-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (24.11 KB - PDF)

**First published:**

08/05/2014

**Last updated:**

28/10/2021

[View](/hu/documents/all-authorised-presentations/deltyba-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (37.57 KB - PDF)

**First published:**

08/05/2014

**Last updated:**

28/10/2021

[View](/mt/documents/all-authorised-presentations/deltyba-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (14.63 KB - PDF)

**First published:**

08/05/2014

**Last updated:**

28/10/2021

[View](/nl/documents/all-authorised-presentations/deltyba-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (14.9 KB - PDF)

**First published:**

08/05/2014

**Last updated:**

28/10/2021

[View](/no/documents/all-authorised-presentations/deltyba-epar-all-authorised-presentations_no.pdf)

polski (PL) (37.3 KB - PDF)

**First published:**

08/05/2014

**Last updated:**

28/10/2021

[View](/pl/documents/all-authorised-presentations/deltyba-epar-all-authorised-presentations_pl.pdf)

português (PT) (15.19 KB - PDF)

**First published:**

08/05/2014

**Last updated:**

28/10/2021

[View](/pt/documents/all-authorised-presentations/deltyba-epar-all-authorised-presentations_pt.pdf)

română (RO) (34.21 KB - PDF)

**First published:**

08/05/2014

**Last updated:**

28/10/2021

[View](/ro/documents/all-authorised-presentations/deltyba-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (36.91 KB - PDF)

**First published:**

08/05/2014

**Last updated:**

28/10/2021

[View](/sk/documents/all-authorised-presentations/deltyba-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (34.06 KB - PDF)

**First published:**

08/05/2014

**Last updated:**

28/10/2021

[View](/sl/documents/all-authorised-presentations/deltyba-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (17.94 KB - PDF)

**First published:**

08/05/2014

**Last updated:**

28/10/2021

[View](/fi/documents/all-authorised-presentations/deltyba-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (13.46 KB - PDF)

**First published:**

08/05/2014

**Last updated:**

28/10/2021

[View](/sv/documents/all-authorised-presentations/deltyba-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Deltyba Active substance Delamanid International non-proprietary name (INN) or common name delamanid Therapeutic area (MeSH) Tuberculosis, Multidrug-Resistant Anatomical therapeutic chemical (ATC) code J04AK06

### Pharmacotherapeutic group

Antimycobacterials

### Therapeutic indication

Deltyba is indicated for use as part of an appropriate combination regimen for pulmonary multi-drug resistant tuberculosis (MDR-TB) in adults, adolescents, children and infants with a body weight of at least 10 kg when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability (see sections 4.2, 4.4 and 5.1).

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

## Authorisation details

EMA product number EMEA/H/C/002552

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Conditional approval

This medicine received a conditional marketing authorisation. This was granted in the interest of public health because the medicine addresses an unmet medical need and the benefit of immediate availability outweighs the risk from less comprehensive data than normally required. For more information, see [Conditional marketing authorisation](/node/68774) .

Orphan

This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see [Orphan designation](/node/69983) .

Marketing authorisation holder

Otsuka Novel Products GmbH

Erika-Mann-Strasse 21

Opinion adopted 21/11/2013 Marketing authorisation issued 27/04/2014 Revision 27

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Deltyba : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (264.05 KB - PDF)

**First published:** 25/07/2014

**Last updated:** 05/05/2025

[View](/en/documents/procedural-steps-after/deltyba-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Deltyba-H-C-PSUSA-00010213-202304: EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/540391/2023

English (EN) (89.33 KB - PDF)

**First published:** 29/02/2024

[View](/en/documents/scientific-conclusion/deltyba-h-c-psusa-00010213-202304-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation_en.pdf)

Deltyba-H-C-PSUSA-00010213-202104 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/723817/2021

English (EN) (120.75 KB - PDF)

**First published:** 22/02/2022

[View](/en/documents/scientific-conclusion/deltyba-h-c-psusa-00010213-202104-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

Deltyba-H-C-002552-X-0046-G : EPAR - Assessment report - Variation

Adopted

Reference Number: EMA/543612/2021

English (EN) (3.08 MB - PDF)

**First published:** 28/10/2021

[View](/en/documents/variation-report/deltyba-h-c-002552-x-0046-g-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Deltyba (X-46-G)

Adopted

Reference Number: EMA/CHMP/266703/2021

English (EN) (137.96 KB - PDF)

**First published:** 23/07/2021

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-deltyba-x-46-g_en.pdf)

Deltyba-H-C-2552-II-0040 : EPAR - Assessment report - Variation

Adopted

Reference Number: EMA/526836/2020

English (EN) (2.85 MB - PDF)

**First published:** 17/12/2020

[View](/en/documents/variation-report/deltyba-h-c-2552-ii-0040-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Deltyba (II-40)

Adopted

Reference Number: EMA/CHMP/316556/2020

English (EN) (131.93 KB - PDF)

**First published:** 18/09/2020

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-deltyba-ii-40_en.pdf)

Deltyba-PSUSA-00010213-201810 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation(s)

Reference Number: EMA/444492/2019

English (EN) (68.32 KB - PDF)

**First published:** 08/08/2019

[View](/en/documents/scientific-conclusion/deltyba-psusa-00010213-201810-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations_en.pdf)

Deltyba-H-C-2552-P46-007 : EPAR - Assessment report

Adopted

Reference Number: EMEA/H/C/002552/P46

English (EN) (758.99 KB - PDF)

**First published:** 13/11/2018

[View](/en/documents/variation-report/deltyba-h-c-2552-p46-007-epar-assessment-report_en.pdf)

## Initial marketing authorisation documents

Deltyba : EPAR - Public assessment report

Adopted

Reference Number: EMA/55567/2014

English (EN) (4.22 MB - PDF)

**First published:** 08/05/2014

**Last updated:** 08/05/2014

[View](/en/documents/assessment-report/deltyba-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Deltyba

Adopted

Reference Number: EMA/CHMP/713909/2013

English (EN) (64.93 KB - PDF)

**First published:** 22/11/2013

**Last updated:** 22/11/2013

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-deltyba_en.pdf)

Questions and answers on refusal of the marketing authorisation for Delamanid

Adopted

Reference Number: EMA/446276/2013

English (EN) (67.88 KB - PDF)

**First published:** 26/07/2013

**Last updated:** 26/07/2013

[View](/en/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-delamanid_en.pdf)

#### News on Deltyba

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 July 2021](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-19-22-july-2021) 23/07/2021

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 14-17 September 2020](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-14-17-september-2020) 18/09/2020

[World TB Day - three new medicines recommended in last six months for patients with multidrug-resistant tuberculosis](/en/news/world-tb-day-three-new-medicines-recommended-last-six-months-patients-multidrug-resistant-tuberculosis) 21/03/2014

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 18-21 November 2013](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-18-21-november-2013) 22/11/2013

[European Medicines Agency recommends two new treatment options for tuberculosis](/en/news/european-medicines-agency-recommends-two-new-treatment-options-tuberculosis) 22/11/2013

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2013](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2013) 26/07/2013

#### More information on Deltyba

- [EU/3/07/524 - orphan designation for treatment of tuberculosis](/en/medicines/human/orphan-designations/eu-3-07-524)
- [EMEA-001113-PIP01-10-M06 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001113-pip01-10-m06)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 05/05/2025

## Share this page

[Back to top](#main-content)